Price$28.20+0.27 (+0.98%)
01:30 PM07:45 PM
News · 26 weeks41-73%
2025-10-262026-04-19
Mix2190d
- Insider10(48%)
- SEC Filings4(19%)
- Earnings3(14%)
- Analyst2(10%)
- Other2(10%)
Latest news
25 items- PRAtriCure to Announce First Quarter 2026 Financial ResultsAtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, May 5, 2026, to discuss its first quarter financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at https://ir.atricur
- SECSEC Form DEFA14A filed by AtriCure Inc.DEFA14A - AtriCure, Inc. (0001323885) (Filer)
- SECSEC Form DEF 14A filed by AtriCure Inc.DEF 14A - AtriCure, Inc. (0001323885) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by AtriCure Inc.SCHEDULE 13G/A - AtriCure, Inc. (0001323885) (Subject)
- INSIDERChief Scientific Officer Doraiswamy Vinayak sold $149,150 worth of shares (5,000 units at $29.83), decreasing direct ownership by 5% to 96,875 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERDirector White Robert S. exercised 10,000 shares at a strike of $14.99, increasing direct ownership by 9% to 122,174 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERPresident, CEO, & Director Carrel Michael H gifted 6,000 shares, decreasing direct ownership by 0.76% to 778,498 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERChief Scientific Officer Doraiswamy Vinayak was granted 45,588 shares and covered exercise/tax liability with 15,585 shares, increasing direct ownership by 42% to 101,875 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERChief Mktg & Strategy Officer Noznesky Justin J was granted 43,189 shares and covered exercise/tax liability with 15,586 shares, increasing direct ownership by 35% to 106,401 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERPresident, CEO, & Director Carrel Michael H covered exercise/tax liability with 72,777 shares and was granted 169,898 shares, increasing direct ownership by 14% to 784,498 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERChief Financial Officer Wirick Angela L was granted 63,088 shares and covered exercise/tax liability with 22,965 shares, increasing direct ownership by 24% to 204,893 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERChief Technical Officer Privitera Salvatore was granted 45,588 shares and covered exercise/tax liability with 13,127 shares, increasing direct ownership by 26% to 158,048 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERChief Legal Officer Dahlquist Karl S. was granted 43,189 shares and covered exercise/tax liability with 15,687 shares, increasing direct ownership by 40% to 96,053 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- INSIDERChief Operating Officer Seith Douglas J was granted 67,918 shares and covered exercise/tax liability with 22,948 shares, increasing direct ownership by 24% to 229,340 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)
- PRAtriCure to Participate in the Citizens Life Sciences ConferenceAtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Citizens Life Sciences Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, March 10, 2026, at 1:05 p.m. Eastern Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company's website at https://ir.atricure.com. About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more tha
- SECSEC Form 10-K filed by AtriCure Inc.10-K - AtriCure, Inc. (0001323885) (Filer)
- ANALYSTAtriCure downgraded by OppenheimerOppenheimer downgraded AtriCure from Outperform to Perform
- SECAtriCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AtriCure, Inc. (0001323885) (Filer)
- PRAtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial ResultsFourth Quarter 2025 worldwide revenue of $140.5 million – an increase of 13.1% year over year Fourth Quarter 2025 net income of $1.8 million and positive adjusted EBITDA of $19.9 million Full Year 2025 worldwide revenue of $534.5 million – an increase of 14.9% year over year Full Year 2025 net loss of $11.4 million and positive adjusted EBITDA of $61.8 million 2025 growth marked by expanding use of new products, including cryoSPHERE® MAX™ and AtriClip FLEX-Mini®, and the continued adoption of EnCompass® clamp AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-o
- ANALYSTAtriCure downgraded by Analyst with a new price targetAnalyst downgraded AtriCure from Overweight to Neutral and set a new price target of $36.00
- PRAtriCure to Announce Fourth Quarter and Full Year 2025 Financial ResultsAtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, February 17, 2026, to discuss its fourth quarter and full year 2025 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio
- PRAI Diagnostics: The End of the High-Cost Imaging EraVANCOUVER, British Columbia, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The AI medical imaging market is entering a phase of explosive 25.8% annual growth through 2034[1]. This systemic re-rating is driven by healthcare's structural pivot from bulky, expensive hardware to agile, software-defined intelligence. As diagnostics move out of specialized labs and into decentralized, point-of-care environments[2], institutions are rotating capital into a first-mover cohort capable of delivering MRI-grade accuracy on the fly. This secular transition is positioning VentriPoint Diagnostics (TSXV:VPT) (OTCPK: VPTDF), Heartflow (NASDAQ:HTFL), AtriCure (NASDAQ:ATRC), Edwards
- PRAtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2025 and provided 2026 financial guidance. Preliminary, unaudited revenue for fourth quarter 2025 is expected to be $140.5 million, reflecting growth of approximately 13% over the fourth quarter of 2024 (12% on a constant currency basis). U.S. revenue is expected to be $114.3 million, reflecting growth of approximately 13%, and international revenue is expected to be $26.2 million, an increase of approximately 15% as
- SECAtriCure Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition8-K - AtriCure, Inc. (0001323885) (Filer)
- INSIDERChief Operating Officer Seith Douglas J was granted 257 shares, increasing direct ownership by 0.14% to 184,370 units (SEC Form 4)4 - AtriCure, Inc. (0001323885) (Issuer)